Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. <br /><br />
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Roche presents restistance-breaking antibiotic
Hoffmann-La Roche AG has published details on <i>the mechanism of action of its Phase I antibiotic Zosurabalpin</i> (RG6006) that kills the carbapenem-resistant bug<i> Acinetobacter baumannii</i>. <br />.
Alfasigma SpA signs €170m deal with Galapagos NV
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal. <div title="Page 1" class="page"><div class="layoutArea"><div class="column"></div></div></div>
AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
Metrion Biosciences closes £3.7m equity financing
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.
LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical <i>Staphylococcus aureus vaccine </i><span style="caret-color: rgb(33, 33, 33); color: rgb(33, 33, 33); font-family: Arial, sans-serif; font-size: 13.333333015441895px; font-style: […]
French parliamentarians against cell-based meat
The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.
Vandria SA raises CHF18m in Series A fnancing
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.
Vandria SA bags CHF18m in Series A financing
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.